We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 07, 2021

Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-Blind, Placebo-Controlled Randomized Clinical Trial
JAMA Dermatol 2021 Aug 18;[EPub Ahead of Print], S Glatt, GBE Jemec, S Forman, C Sayed, G Schmieder, J Weisman, R Rolleri, S Seegobin, D Baeten, L Ionescu, CC Zouboulis, S Shaw

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading